{
    "clinical_study": {
        "@rank": "146219", 
        "arm_group": {
            "arm_group_label": "oxycodone/naloxone", 
            "arm_group_type": "Other", 
            "description": "oral, TID"
        }, 
        "brief_summary": {
            "textblock": "Objectives:\n\n        1. Objective of main interest\n\n           - To assess the drop-out rate caused by adverse event* after 6 weeks treatment\n\n        2. Further objectives\n\n             -  To assess the drop-out rate caused by adverse event* after 1 week treatment\n\n             -  To assess the pain reduction rate after 6 weeks treatment from baseline\n\n             -  To assess the EQ-5D\n\n             -  To assess physician's overall satisfaction\n\n             -  To assess subject's overall satisfaction\n\n             -  To assess safety"
        }, 
        "brief_title": "An Interventional Study to Compare the Efficacy and Tolerability With TARGIN\u00ae in Non-malignant Chronic Pain (GLORY)", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Pain", 
        "detailed_description": {
            "textblock": "Study Design (Methodology):\n\n      This will be a single center, open-label, randomised, phase IV, exploratory interventional\n      study to compare the efficacy and tolerability of current titration patterns and slow\n      titration pattern with TARGIN\u00ae (Oxycodone/Naloxone) in the treatment of moderate to severe\n      non-malignant chronic pain patients who are dissatisfied with their current analgesic\n      medication (WHO step II analgesics).\n\n      Upon providing written informed consent, subject will be screened in the study and\n      assessment will be performed at that time such as safety laboratory assessments, physical\n      examination, vital sign, medical history taking, 24 hours pain intensity score. If the\n      patient is eligible in inclusion/exclusion criteria at the time of visit 1, the patient will\n      be randomized in a 1:1 ratio to allocate in Group A or Group B. Re-screening, study drug\n      dose interruption is not allowed."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female \u2265 20 and <80 years of age\n\n          -  Patients who have non-malignant chronic pain(\u226590 days)\n\n          -  Patients who have moderate to severe pain intensity which is not controlled with\n             non-strong opioid\n\n          -  Na\u00efve patients for Oxycodone/Naloxone (Na\u00efve patient defined as who did not treated\n             for 90 days)\n\n          -  Na\u00efve patients for strong opioid (Na\u00efve patient defined as who did not treated for 90\n             days)\n\n          -  Patients who signed a written informed consent form\n\n        Exclusion Criteria:\n\n          -  Women of child-bearing potential, defined as all women physiologically capable of\n             becoming pregnant.\n\n          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a\n             female after conception and until the termination of gestation, confirmed by a\n             positive urine pregnancy test\n\n          -  Patients with known hypersensitivity to Oxycodone/Naloxone or to any of the\n             excipients\n\n          -  Patient who needs acute dose titration or whose pain intensity fluctuate\n             significantly in a short period according to investigator's judgment\n\n          -  Having used other investigational drugs at the time of enrollment, or within 30 days\n             of enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "260", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01811186", 
            "org_study_id": "OXN12_KR_403"
        }, 
        "intervention": {
            "arm_group_label": "oxycodone/naloxone", 
            "description": "oral, TID", 
            "intervention_name": "oxycodone/naloxone", 
            "intervention_type": "Drug", 
            "other_name": "Targin"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Naloxone", 
                "Oxycodone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "moderate to severe non-malignant chronic pain", 
        "lastchanged_date": "December 9, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "AMC"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Interventional Study to Compare the Efficacy and Tolerability of Current and Slow Titration With TARGIN\u00ae in the Treatment of Moderate to Severe Non-malignant Chronic Pain (GLORY)", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Korea: Food and Drug Administration", 
                "Korea: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To assess the drop-out rate caused by adverse event* after 6 weeks treatment", 
            "measure": "drop-out rate caused by adverse event", 
            "safety_issue": "Yes", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01811186"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Mundipharma Korea Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mundipharma Korea Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}